Breast cancer claims the lives of approximately 670,000 individuals each year. According to data from the World Health Organization (WHO), breast cancer was the most prevalent form of cancer in women in 157 out of 185 countries in 2022. Over 2 million women are diagnosed with breast cancer annually. This highlights the need for early detection of this deadly disease and the development of targeted treatments for cancerous cells. The US Food and Drug Administration (FDA) has approved Kisqali, also known as ribociclib, for the treatment of early stage breast cancer. This drug is to be used in combination with hormone therapy for patients in the early stages of breast cancer. This approval will benefit patients concerned about cancer recurrence. The FDA has approved ribociclib with an aromatase inhibitor for adjuvant treatment in adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. Additionally, the FDA has authorized the use of the ribociclib and letrozole co-pack for the same purpose. Ribociclib, also known as Kisqali, is a selective cyclin-dependent kinase inhibitor that works by slowing cancer progression through inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). Novartis, the manufacturer, explains that over-activation of these proteins can accelerate the growth and division of cancer cells. By precisely targeting CDK4/6, it is possible to prevent cancer cells from replicating uncontrollably. Kisqali (ribociclib) is administered as an oral pill, typically prescribed for three weeks with a one-week break, to be continued for three years. It can be taken with or without food, and a daily oral dose of 400 mg is recommended.Kisqali: Side Effects

Common side effects of Kisqali medication include low white blood cell count known as neutropenia. Neutropenia is characterized by reduced levels of neutrophils in the blood, which are crucial for fighting infection. In addition, Kisqali may also cause liver problems and interstitial lung disease/pneumonitis.

Breast Cancer: Warning Signs You Shouldn't Overlook